The Postanesthesia Care Unit - Considerations for Pediatric Recovery
To view the entire topic, please log in or purchase a subscription.
Anesthesia Central is an all-in-one web and mobile solution for treating patients before, during, and after surgery. This collection of drugs, procedures, and test information is derived from Davis’s Drug, MGH Clinical Anesthesia Procedures, Pocket Guide to Diagnostic Tests, and PRIME Journals. Explore these free sample topics:
-- The first section of this topic is shown below --
PONV
PONV is more common in the pediatric surgery population than in adults; however, children under the age of 2 years old are exceptions and have a reduced incidence relative to adults. Certain operations (adenotonsillectomy, strabismus repair, hernia repair, orchidopexy, and penile surgery) are associated with increased incidence for PONV. Risk factors, as well as the general principles for prevention and treatment, are similar to those described in adults. There is reasonable evidence to suggest ondansetron (100 μg/kg IV bolus for <6 months old; 150 μg/kg IV bolus >6 months old up to 4 mg) and dexamethasone (62.5 to 500 μg/kg up to 8 mg) are superior to other drugs in the prevention of PONV in children.
-- To view the remaining sections of this topic, please log in or purchase a subscription --
PONV
PONV is more common in the pediatric surgery population than in adults; however, children under the age of 2 years old are exceptions and have a reduced incidence relative to adults. Certain operations (adenotonsillectomy, strabismus repair, hernia repair, orchidopexy, and penile surgery) are associated with increased incidence for PONV. Risk factors, as well as the general principles for prevention and treatment, are similar to those described in adults. There is reasonable evidence to suggest ondansetron (100 μg/kg IV bolus for <6 months old; 150 μg/kg IV bolus >6 months old up to 4 mg) and dexamethasone (62.5 to 500 μg/kg up to 8 mg) are superior to other drugs in the prevention of PONV in children.
There's more to see -- the rest of this entry is available only to subscribers.